Ultragenyx Pharmaceutical, Inc. (RARE)
NASDAQ:RARE
Want to see RARE full AI Analyst Report?
RARE Stock Chart & Stats
$24.81
-$0.60(-1.35%)
At close: 4:00 PM EST
$24.81
-$0.60(-1.35%)
Day’s Range― - ―
52-Week Range$18.29 - $42.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)1.73M
Market Cap
$3.03B
Enterprise Value$3.68B
Total Cash (Recent Filing)$413.00M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Jul 30, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.11
Shares Outstanding98,489,230
10 Day Avg. Volume2,003,287
30 Day Avg. Volume1,731,177
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue5.49
Enterprise Value/Gross Profit6.57
Enterprise Value/Ebitda-7.30
Forecast
1Y Price Target
$53.79Price Target Upside116.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.51
Revenue Forecast (FY)$741.44M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsTTM gross margin of ~84% indicates durable pricing power and favorable cost structure for biologics. With multiple marketed rare-disease products, high gross margins create potential for rapid operating leverage as revenue scales and management reins in R&D/SG&A.
Global Commercial ScaleEstablished sales in >35 countries and growing patient counts (Crysvita, Dojolvi, Evkeeza) reflect durable market access, reimbursement relationships, and specialty distribution. This geographic diversification reduces single-market exposure and supports sustained product revenue growth.
Near-term Regulatory CatalystsPDUFA timelines for DTX401 and UX111 plus a pending GTX-102 Phase 3 readout are structural catalysts: approvals would add high-margin, durable revenue streams and validate gene-therapy capabilities, supporting long-term revenue diversification and justifying manufacturing investments.
Bears Say
Heavy Cash BurnPersistent negative operating cash flow and free cash flow signal material ongoing cash consumption. Continued burn reduces runway, forces reliance on external financing or one-time monetizations, elevates dilution risk, and constrains ability to fund launches and scale manufacturing.
Weak Balance SheetNegative equity and roughly $1.2B of debt create elevated leverage and reduced financial flexibility. Structurally weaker balance sheet increases refinancing and covenant risk, limiting ability to absorb launch setbacks or invest opportunistically without dilutive capital raises.
Dependence On Non-operating Receipts & ExecutionManagement’s profitability plan relies materially on monetizing PRVs and timely successful launches. Dependence on one‑time voucher proceeds and precise execution/timing for gene-therapy approvals creates structural revenue uncertainty; shortfalls would necessitate additional funding or expense cuts.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?
Ultragenyx Pharmaceutical, Inc. lowest stock price was $18.29 and its highest was $42.37 in the past 12 months.
What is Ultragenyx Pharmaceutical, Inc.’s market cap?
Ultragenyx Pharmaceutical, Inc.’s market cap is $3.03B.
When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?
Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?
Ultragenyx Pharmaceutical, Inc. released its earnings results on May 05, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.488 by -$0.352.
Is Ultragenyx Pharmaceutical, Inc. overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical, Inc. pay dividends?
Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.
What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?
Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -1.22.
How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?
Ultragenyx Pharmaceutical, Inc. has 98,489,230 shares outstanding.
What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?
Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.488. Following the earnings report the stock price went up 3.679%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.79 (116.79% Upside)
$53.79 (116.79% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $566.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.10%
12-Months-Change
Fundamentals
Return on Equity
1566.94%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
RARE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances strong commercial execution, clear revenue guidance (reaffirmed $730M–$760M for 2026), rapid pipeline progress (two near-term PDUFAs and promising long-term GTX-102 data with Bayley-4 and MDRI signals), and manufacturing/launch readiness against meaningful near-term financial pressure (Q1 net loss of $185M, $197M cash used in operations, high operating expenses and restructuring charges). Management presented a credible path to profitability in 2027 with planned R&D/SG&A reductions and assumed PRV monetization, but timing uncertainty for Phase 3 readouts, quarter-to-quarter ordering variability and execution risks around launches and PRV realization remain. Overall the positives around product performance, global commercialization scale, and upcoming catalysts outweigh the near-term financial and execution risks.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$53.79
▲(116.79% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.97% Insiders
19.36% Mutual Funds
38.21% Other Institutional Investors
22.25% Public Companies and Individual Investors